New U.S. Patent Allowance Strengthens Protection for CAPTN-3 Modular Platform for Next-Generation Multispecific AntibodiesGlobeNewsWire · Sep 2, 2026
Financial Review: Ionis Pharmaceuticals (NASDAQ:IONS) & Purple Biotech (NASDAQ:PPBT)Defense World · Aug 31, 2026
Purple Biotech (PPBT) Expected to Announce Quarterly Earnings on WednesdayDefense World · Aug 4, 2026Purple Biotech Ltd., a clinical-stage biotechnology firm based in Rehovot, Israel, is dedicated to pioneering treatments that help cancer patients, particularly in the United States, overcome tumor immune evasion and drug resistance. Its pipeline features two primary oncology assets: CM24: A monoclonal antibody designed to block carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). This candidate is undergoing Phase 1b/2 clinical trials, where it is being evaluated as a combination therapy with anti-PD-1 checkpoint inhibitors for non-small cell lung cancer and pancreatic cancer.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 7, 2026 | -$0.98 | $1.07 | Beat |
| May 15, 2026 | -$3.80 | -$0.09 | Beat |
| Mar 13, 2026 | -$3.40 | -$19.85 | Miss |
| Nov 14, 2025 | -$2.60 | -$2.90 | Miss |
| Aug 6, 2025 | -$2.10 | -$4.00 | Miss |
| May 21, 2025 | – | -$1.70 |